AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21298444 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral hopping intervention (5-7 sets of 10 s timed bilateral hopping exercise at 75-90% intensity three times/week)
Number of subjects: 25
Study 21298444 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study 21298444 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral hopping intervention
Number of subjects: 25
Study 20027365 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoten and Tenoten (pediatric formulation)
Number of subjects: 0
Study 17578751 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine (1500 mg per day)
Number of subjects: 106
Study 17578751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 15539864 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 88
Study 15539864 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 88
Study 15539864 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amitriptyline and citalopram
Number of subjects: 88
Study 11314213 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% benzalkonium chloride solution
Number of subjects: 25
Study 11314213 — intervention group
Group type: EXPERIMENTAL
Intervention: 32% phosphoric acid with benzalkonium chloride
Number of subjects: 25
Study 11314213 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% phosphoric acid
Number of subjects: 25
Study 11314213 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% maleic acid
Number of subjects: 25
Study 9503181 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus ticlopidine (250 mg)
Number of subjects: 52
Study 9503181 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg)
Number of subjects: 52
Study 8005815 — intervention group
Group type: EXPERIMENTAL
Intervention: Estramustine phosphate (EMP) plus Velban with concomitant radiotherapy (RT)
Number of subjects: 27
Study 8005815 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 27
Study 2586565 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical treatment
Number of subjects: 299
Study 2586565 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneovenous (LeVeen) shunting
Number of subjects: 299
Study 10953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous labetalol at a dose of 1 mg/kg
Number of subjects: 15
Study 10953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous labetalol at a dose of 2 mg/kg
Number of subjects: 15
Study 10953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous labetalol at a dose of 1 mg/kg and 2 mg/kg
Number of subjects: 15
Study 31811662 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Technosphere Insulin
Number of subjects: 375
Study 31811662 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin aspart
Number of subjects: 375
Study 30947511 — intervention group
Group type: EXPERIMENTAL
Intervention: ECGI (CardioInsight)
Number of subjects: 8
Study 30947511 — intervention group
Group type: COMPARATOR
Intervention: CARTO (Biosense‐Webster, CA)
Number of subjects: 8
Study 30947511 — intervention group
Group type: EXPERIMENTAL
Intervention: ECGI and CARTO comparison
Number of subjects: 8
Study 28395180 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir-based regimen (RASTA group)
Number of subjects: 58
Study 28395180 — intervention group
Group type: COMPARATOR
Intervention: PI or NNRTI based-regimen (controls)
Number of subjects: 58
Study 25563351 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (educational training, structured process change, review methods, patient education)
Number of subjects: 12
Study 25563351 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study 25563351 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 12
Study 23107581 — intervention group
Group type: EXPERIMENTAL
Intervention: DSAEK
Number of subjects: 173
Study 23107581 — intervention group
Group type: COMPARATOR
Intervention: PKP
Number of subjects: 173
Study 22198600 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum flexed position compared to standing position
Number of subjects: 5
Study 22198600 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated position compared to standing position
Number of subjects: 5
Study 18840027 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5 mg
Number of subjects: 12
Study 18840027 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg
Number of subjects: 12
Study 18840027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16839780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (30 mg)
Number of subjects: 34
Study 16839780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 12574793 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril 30 mg + Indapamide 1.25 mg (D+I)
Number of subjects: 790
Study 12574793 — intervention group
Group type: COMPARATOR
Intervention: Captopril 50 mg + Hydrochlorothiazide 15 mg (C+H)
Number of subjects: 790
Study 10990236 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive home based knee exercise program
Number of subjects: 179
Study 10990236 — intervention group
Group type: COMPARATOR
Intervention: Control program (sham exercise)
Number of subjects: 179
Study 9358722 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium contrast studies
Number of subjects: 64
Study 9358722 — intervention group
Group type: COMPARATOR
Intervention: Plain abdominal X-rays
Number of subjects: 64
Study 1545660 — intervention group
Group type: EXPERIMENTAL
Intervention: CAAD (diphenhydramine hydrochloride, 50 mg; pseudoephedrine hydrochloride, 60 mg; acetaminophen, 1 g in 10% ethanol)
Number of subjects: 18
Study 1545660 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (single dose)
Number of subjects: 18
Study 1545660 — intervention group
Group type: EXPERIMENTAL
Intervention: CAAD
Number of subjects: 18
Study 1545660 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 18
Study 1545660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3872241 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Nd:YAG laser therapy
Number of subjects: 20
Study 3872241 — intervention group
Group type: COMPARATOR
Intervention: Sham endoscopy and standard medical therapy (Control)
Number of subjects: 20
Study 29135832 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 25
Study 29135832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 27520400 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 40mg/day (Resv40arm)
Number of subjects: 192
Study 27520400 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 500mg/day (Resv500arm)
Number of subjects: 192
Study 27520400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 24100705 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment for back pain and VCF
Number of subjects: 82
Study 24100705 — intervention group
Group type: COMPARATOR
Intervention: Insufficient pain relief group
Number of subjects: 82
Study 24100705 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 82
Study 22425507 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate, 35 mg once weekly
Number of subjects: 86
Study 22425507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 22425507 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 86
Study 22425507 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate and Placebo
Number of subjects: 86
Study 20868284 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell culture-derived influenza vaccine (CCIV)
Number of subjects: 11404
Study 20868284 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg-derived trivalent inactivated vaccine (TIV)
Number of subjects: 11404
Study 20868284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11404
Study 19024795 — intervention group
Group type: EXPERIMENTAL
Intervention: Glabridin (60 mg)
Number of subjects: 0
Study 15737670 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (300 mg/day)
Number of subjects: 39
Study 15737670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 12745493 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent payment based on breath carbon monoxide levels (CO <= 8 ppm)
Number of subjects: 0
Study 12745493 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent payment with differing amounts based on breath carbon monoxide levels
Number of subjects: 0
Study 12745493 — intervention group
Group type: COMPARATOR
Intervention: Control group with noncontingent payment
Number of subjects: 0
Study 12879120 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 3
Study 12879120 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotic therapies
Number of subjects: 3
Study 8973995 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg) with prednisone (40 mg)
Number of subjects: 18
Study 8973995 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg) with prednisone (40 mg)
Number of subjects: 18
Study 8973995 — intervention group
Group type: COMPARATOR
Intervention: Placebo with prednisone (40 mg)
Number of subjects: 18
Study 1283847 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy (single-agent tamoxifen)
Number of subjects: 0
Study 1283847 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with endocrine therapy
Number of subjects: 0
Study 1283847 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 1283847 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of chemotherapy with colony-stimulating factors and bone marrow transplantation
Number of subjects: 0
Study 1283847 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endocrine therapy
Number of subjects: 0
Study 3931537 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + glibenclamide 5 mg twice daily
Number of subjects: 9
Study 3931537 — intervention group
Group type: COMPARATOR
Intervention: Insulin + placebo
Number of subjects: 9
Study 30646879 — intervention group
Group type: EXPERIMENTAL
Intervention: Group schema-focused therapy enriched with psychomotor therapy (SFT + PMT)
Number of subjects: 0
Study 30646879 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 28597302 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood pressure at admission
Number of subjects: 2468
Study 28597302 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in blood pressure after extubation
Number of subjects: 2468
Study 28597302 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative drainage
Number of subjects: 2468
Study 28597302 — intervention group
Group type: COMPARATOR
Intervention: Pre-operative hypertension treatment
Number of subjects: 2468
Study 26600039 — intervention group
Group type: COMPARATOR
Intervention: Ventral shell spring-hinged AFO (vAFO) - rigid setting
Number of subjects: 15
Study 26600039 — intervention group
Group type: COMPARATOR
Intervention: Ventral shell spring-hinged AFO (vAFO) - spring-like setting
Number of subjects: 15
Study 26600039 — intervention group
Group type: COMPARATOR
Intervention: All vAFOs
Number of subjects: 15
Study 23644914 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch applied to smokers during nicotine withdrawal
Number of subjects: 0
Study 23644914 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch applied to smokers
Number of subjects: 0
Study 23644914 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch applied to non-smokers
Number of subjects: 0
Study 23644914 — intervention group
Group type: COMPARATOR
Intervention: Smokers during nicotine withdrawal
Number of subjects: 0
Study 22333098 — intervention group
Group type: EXPERIMENTAL
Intervention: Marvelon (30 µg ethinylestradiol and 150 µg desogestrel) for 21 days
Number of subjects: 188
Study 22333098 — intervention group
Group type: EXPERIMENTAL
Intervention: Progynova 2 mg/d for 21 days and depogesterone 10 mg/d for last 5 days
Number of subjects: 188
Study 22333098 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 188
Study 22333098 — intervention group
Group type: EXPERIMENTAL
Intervention: Marvelon and Progynova/Depogesterone
Number of subjects: 188
Study 22333098 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 188
Study 19350266 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 86
Study 19350266 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 86
Study 16458092 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 44
Study 16458092 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%
Number of subjects: 44
Study 16458092 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 44
Study 16458092 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 44
Study 15303255 — intervention group
Group type: EXPERIMENTAL
Intervention: Ylang-ylang oil (Cananga odorata) inhalation
Number of subjects: 24
Study 15303255 — intervention group
Group type: COMPARATOR
Intervention: Odorless placebo
Number of subjects: 24
Study 11417953 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (1 microg/kg/min)
Number of subjects: 48
Study 11417953 — intervention group
Group type: COMPARATOR
Intervention: Control group (without renal dysfunction)
Number of subjects: 48
Study 11417953 — intervention group
Group type: COMPARATOR
Intervention: Control group (with renal dysfunction)
Number of subjects: 48
Study 9813876 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% glucose polymer (G)
Number of subjects: 8
Study 9813876 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% fructose (F)
Number of subjects: 8
Study 9813876 — intervention group
Group type: COMPARATOR
Intervention: Sweet placebo (P)
Number of subjects: 8
Study 7816382 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole infusion
Number of subjects: 42
Study 7816382 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial SPECT with 99Tcm-sestamibi
Number of subjects: 42
Study 7816382 — intervention group
Group type: COMPARATOR
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 42
Study 3234614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 120
Study 3234614 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimoprostil 3 mg twice daily
Number of subjects: 120
Study 3234614 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimoprostil 3 mg at bedtime
Number of subjects: 120
Study 31821741 — intervention group
Group type: EXPERIMENTAL
Intervention: History of autoimmune disease
Number of subjects: 3112
Study 31821741 — intervention group
Group type: EXPERIMENTAL
Intervention: History of allergy
Number of subjects: 3112
Study 31821741 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of immunosuppressive drugs
Number of subjects: 3112
Study 31821741 — intervention group
Group type: EXPERIMENTAL
Intervention: History of inflammatory bowel disease (IBD)
Number of subjects: 3112
Study 31821741 — intervention group
Group type: EXPERIMENTAL
Intervention: History of asthma
Number of subjects: 3112
Study 31821741 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term duration diabetes
Number of subjects: 3112
Study 30139624 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk with 80:20 casein-to-whey protein ratio at 3.1% concentration
Number of subjects: 32
Study 30139624 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk with 40:60 casein-to-whey protein ratio at 3.1% concentration
Number of subjects: 32
Study 30139624 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk with 80:20 casein-to-whey protein ratio at 9.3% concentration
Number of subjects: 32
Study 30139624 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk with 40:60 casein-to-whey protein ratio at 9.3% concentration
Number of subjects: 32
Study 30139624 — intervention group
Group type: COMPARATOR
Intervention: Control (water with whey permeate)
Number of subjects: 32
Study 28346730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese supplemented with Lactobacillus acidophilus NCFM (T1)
Number of subjects: 60
Study 28346730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese supplemented with Lactobacillus rhamnosus Lr‐32 (T2)
Number of subjects: 60
Study 28346730 — intervention group
Group type: COMPARATOR
Intervention: Control cheese (C)
Number of subjects: 60
Study 26335087 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) 1,470 mg/d plus 147 mg/d of eicosapentaenoic acid (EPA)
Number of subjects: 110
Study 26335087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 26335087 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 110
Study 23061976 — intervention group
Group type: EXPERIMENTAL
Intervention: Q/LAIV delivered using a BFS device
Number of subjects: 1800
Study 23061976 — intervention group
Group type: COMPARATOR
Intervention: T/LAIV (trivalent live attenuated influenza vaccine)
Number of subjects: 1800
Study 21727881 — intervention group
Group type: COMPARATOR
Intervention: Postoperative dressings (Control group)
Number of subjects: 123
Study 21727881 — intervention group
Group type: EXPERIMENTAL
Intervention: No postoperative dressings (Study group)
Number of subjects: 123
Study 18354393 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot leuprolide acetate (Lupron) every 4 weeks for 3 months (men) or 5 months (women) + testosterone enanthate (200 mg intramuscularly) every 2 weeks for 1 month (men)
Number of subjects: 40
Study 18354393 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot leuprolide acetate (Lupron) every 4 weeks for 5 months (women) + estradiol and progesterone for 5 weeks each
Number of subjects: 40
Study 18354393 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for men during the testosterone phase)
Number of subjects: 40
Study 17006278 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal CAIV-T (live attenuated cold-adapted influenza vaccine)
Number of subjects: 2229
Study 17006278 — intervention group
Group type: COMPARATOR
Intervention: Injectable TIV (trivalent inactivated influenza vaccine)
Number of subjects: 2229
Study 17006278 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal CAIV-T
Number of subjects: 2229
Study 17006278 — intervention group
Group type: COMPARATOR
Intervention: Injectable TIV
Number of subjects: 2229
Study 17006278 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal CAIV-T and Injectable TIV
Number of subjects: 2229
Study 12733421 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrogators with guilty expectations
Number of subjects: 52
Study 12733421 — intervention group
Group type: COMPARATOR
Intervention: Interrogators with innocent expectations
Number of subjects: 52
Study 12733421 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral observers listening to audiotapes
Number of subjects: 52
Study 10694188 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 2259
Study 10694188 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 2259
Study 9201603 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione i.v. administration (1 g/m2 bolus + 1 g/m2 in 2 h)
Number of subjects: 20
Study 9201603 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test + glutathione administration
Number of subjects: 20
Study 9201603 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose tolerance test
Number of subjects: 20
Study 8450082 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical interdental cleaning plus toothbrushing
Number of subjects: 92
Study 8450082 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial mouthrinse (0.12% chlorhexidine gluconate) plus toothbrushing
Number of subjects: 92
Study 8450082 — intervention group
Group type: COMPARATOR
Intervention: Toothbrushing alone
Number of subjects: 92
Study 3426836 — intervention group
Group type: EXPERIMENTAL
Intervention: L-phenylalanine (high phe)
Number of subjects: 9
Study 3426836 — intervention group
Group type: EXPERIMENTAL
Intervention: L-alanine (low phe)
Number of subjects: 9
Study 3426836 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted diet
Number of subjects: 9
Study 30002145 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg once daily, or 15 mg based on kidney function)
Number of subjects: 120
Study 30002145 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (international normalized ratio target 2.5)
Number of subjects: 120
Study 30002145 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban vs Warfarin
Number of subjects: 120
Study 27820761 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone coaching
Number of subjects: 0
Study 27820761 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group coaching
Number of subjects: 0
Study 27820761 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-study
Number of subjects: 0
Study 25411740 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPDGF + β-TCP
Number of subjects: 15
Study 25411740 — intervention group
Group type: COMPARATOR
Intervention: β-TCP alone
Number of subjects: 15
Study 22672058 — intervention group
Group type: COMPARATOR
Intervention: Inulin 10 g
Number of subjects: 20
Study 22672058 — intervention group
Group type: COMPARATOR
Intervention: Inulin 20 g
Number of subjects: 20
Study 22672058 — intervention group
Group type: EXPERIMENTAL
Intervention: SGF 40 g (acute consumption)
Number of subjects: 20
Study 22672058 — intervention group
Group type: EXPERIMENTAL
Intervention: SGF 65 g (spread over the day)
Number of subjects: 20
Study 20690168 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma Risk Management (TRiM)
Number of subjects: 12
Study 20690168 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 12
Study 17927795 — intervention group
Group type: EXPERIMENTAL
Intervention: ReCell treatment
Number of subjects: 5
Study 17927795 — intervention group
Group type: COMPARATOR
Intervention: Conventional melanocyte-keratinocyte transplantation (MKT)
Number of subjects: 5